Roche to Present Over 30 Oncology Abstracts at ESMO 2025, Showcasing Breakthroughs Across Major Cancer Types
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it will present more than 30 scientific abstracts spanning over 10 cancer types at the European Society for Medical Oncology (ESMO) Congress 2025, taking place from October 17 to 21, 2025, in Berlin, Germany. The breadth of data highlights Roche’s enduring commitment to advancing oncology research and developing transformative medicines for some of the most complex and life-threatening cancers, including breast, lung, gastrointestinal, and genitourinary cancers.
The company’s latest presentations underscore the strength and diversity of its oncology portfolio and pipeline, which integrates precision medicine, novel targeted therapies, and innovative immuno-oncology approaches.
Key Highlights from Roche’s ESMO 2025 Program
1. Giredestrant: Phase III evERA Breast Cancer Study
A central highlight of Roche’s presence at ESMO 2025 is the primary results from the pivotal Phase III evERA Breast Cancer trial, which represents the first positive head-to-head Phase III study evaluating a selective oestrogen receptor (ER) degrader-containing regimen compared with a standard of care combination. The trial involved patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer who had previously received treatment with a cyclin-dependent kinase (CDK) inhibitor.
The study successfully met both of its co-primary endpoints, demonstrating statistically significant and clinically meaningful improvements in progression-free survival (PFS) for both the overall intention-to-treat population and for patients with ESR1-mutated tumors. The data will be shared as a late-breaking oral abstract, marking an important step in the evolution of endocrine therapy options for advanced breast cancer.
2. Tecentriq: ctDNA-Guided Therapy in Bladder Cancer
Roche will also present results from the IMvigor011 trial, the first global Phase III study to implement a circulating tumor DNA (ctDNA)-guided approach to post-surgical treatment in muscle-invasive bladder cancer (MIBC).
Findings show that patients with detectable ctDNA who received Tecentriq® (atezolizumab) experienced statistically significant and clinically meaningful improvements in both disease-free survival (DFS) and overall survival (OS) compared with placebo. These groundbreaking data, which will be presented during the Presidential Symposium, mark a paradigm shift in personalized adjuvant therapy for bladder cancer—demonstrating how ctDNA-based monitoring can guide treatment decisions and potentially improve outcomes for high-risk patients.
3. Alecensa: Long-Term Survival Data in ALK-Positive Lung Cancer
Roche’s targeted therapy Alecensa® (alectinib) continues to redefine standards in lung cancer care. The company will present final overall survival (OS) data from the pivotal ALEX trial, which established Alecensa as a first-line treatment and standard of care for patients with advanced ALK-positive non-small cell lung cancer (NSCLC).
These results, to be shared as a late-breaking oral abstract and published simultaneously in the Annals of Oncology, reinforce Alecensa’s long-term efficacy and tolerability profile compared with crizotinib, further cementing its role in ALK-positive NSCLC management.
Additionally, updated data from the Phase III ALINA study will be presented, providing insights into the adjuvant use of Alecensa in early-stage ALK-positive NSCLC. After approximately four years of median follow-up, the findings continue to support Alecensa as the standard of care for resected patients, demonstrating a prolonged disease-free survival advantage compared with chemotherapy.
Overview of Key Presentations
Breast Cancer:
- Giredestrant (GIRE): Late-breaking oral presentation (#LBA16) in the Proffered Paper Session on Metastatic Breast Cancer on October 18.
- EMPRESS Study: A mini-oral presentation (#294MO) exploring preoperative treatment with giredestrant or tamoxifen in premenopausal women with early-stage ER-positive, HER2-negative breast cancer.
- MORPHEUS Breast Cancer Trial: Poster presentation (#508P) on the interim analysis of giredestrant + inavolisib (Itovebi™) combination therapy.
- Inavolisib Triplet Study: Poster (#548P) evaluating inavolisib combined with pertuzumab and trastuzumab for PIK3CA-mutated, HER2-positive advanced breast cancer.
Genitourinary Cancer:
- Tecentriq (IMvigor011): Late-breaking oral (#LBA8) during the Presidential Symposium III on October 20, presenting the ctDNA-guided adjuvant treatment approach in MIBC.
Lung Cancer:
- Alecensa (ALEX Trial): Late-breaking oral (#LBA73) presenting final OS and safety outcomes in ALK-positive NSCLC on October 17.
- ALINA Study: Mini-oral (#1787MO) providing updated disease-free survival results from adjuvant Alecensa vs chemotherapy on October 20.
- IMforte Study: Mini-oral (#2762MO) analyzing disease progression patterns in small-cell lung cancer treated with lurbinectedin + Tecentriq.
Gastrointestinal Cancer:
- Tecentriq (NCI/Alliance IIS): Poster (#752P) reporting outcomes in stage III colon cancer with deficient mismatch repair (dMMR), comparing adjuvant FOLFOX alone vs with atezolizumab.
- Divarasib: Mini-oral (#927MO) detailing single-agent efficacy in KRAS G12C-mutated pancreatic, cholangiocarcinoma, and other solid tumors.
Roche’s Ongoing Leadership in Oncology
For more than six decades, Roche has been a driving force in transformative oncology innovation, delivering groundbreaking medicines and diagnostics that have redefined the standards of cancer treatment. The company focuses its efforts on high-impact cancers—including breast, lung, and hematologic malignancies—while also pioneering new approaches in tumors of unmet need.
Roche’s oncology pipeline spans a diverse range of therapeutic modalities, from small molecules and monoclonal antibodies to next-generation antibody-drug conjugates (ADCs) and allogeneic CAR T-cell therapies. By integrating precision medicine, novel combination regimens, and advanced data-driven tools, Roche continues to pursue its mission of transforming cancer care and ultimately achieving its vision of a future where cancer can be cured
